GlassScriptPhysician profile
Anne M Anderson
NPI 1679207450
$2,618.79
in general payments reported to CMS, 2019-2025
26 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $181 · 2023: $741 · 2024: $1,175 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,437.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $505.58 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $428.29 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $192.13 | 2023-2024 | Repatha, Otezla |
| Abbvie INC. | $187.92 | 2023-2025 | |
| Pfizer INC. | $176.59 | 2023-2025 | |
| Insulet Corporation | $149.98 | 2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $122.43 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.37 | 2023-2024 | Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $87.05 | 2022-2025 | Spravato, Xarelto |
| Astellas Pharma US INC | $83.76 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $82.33 | 2022-2024 | |
| Glaxosmithkline, LLC. | $82.01 | 2023-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $77.57 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Corcept Therapeutics | $49.27 | 2023-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $33.02 | 2025 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $32.77 | 2023-2024 | Qsymia |
| Idorsia Pharmaceuticals US INC | $30.48 | 2022-2024 | Quviviq |
| Biogen, INC. | $27.64 | 2025 | Leqembi |
| Phathom Pharmaceuticals, INC. | $27.46 | 2024 | Voquezna |
| Noven Therapeutics, LLC | $24.74 | 2024 | Xelstrym |
| Mallinckrodt Hospital Products INC. | $23.54 | 2024 | Acthar |
| Medline Industries LP | $21.78 | 2023 | |
| Dynavax Technologies Corporation | $20.26 | 2024 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $17.64 | 2023 | |
| Dexcom, INC. | $15.13 | 2023 | Dexcom G6 Transmitter |
| Neos Therapeutics, LP | $13.05 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.